Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,otherCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,country,website,maxAge,address1,industry
t0,IF0.DE,138530887,44186300,4906885,,-6125378,,-6125378,3022338,0,-7924326,-7924326,-4897,-3684,,,,0,0,7924326,0,1798948,,-6125378,-6125378,320645,280261994,8398626,138851532,358217,147250158,5302354,5085261,-174470998,34353,27758182,358767,78734662,8226687,27758182,841275,145457028,272443,58834268,1360125,7107880,-1032504.0,-1150252.0,-1049566.0,-90716.0,61796346.0,-3451743.0,66106284.0,52765982.0,2432654.0,-10413453.0,168343.0,-4219222.0,145577.0,-17062.0,,137230341,en-US,US,EQUITY,False,Delayed Quote,EUR,False,False,0,0.24000013,0.12631586,1.9 - 5.798,-3.6579998,-0.6309072,1.9,5.798,-1.1,-2.3722541,2.14 - 2.14,2.192,2.126,2.21,finmb_42434000,XETRA,InflaRx N.V.,EUR,3575,2531,3.142,2.1418571,-0.0018570423,-0.00086702436,2.8517466,-0.71174645,-0.24958265,94558688,0.6810949,15,Europe/Berlin,CEST,7200000,4,GER,REGULAR,de_market,"INFLARX N.V.  EO 0,12",2.14,1630569119,-0.051999807,2.14,2.14,2.14,1000,0.48,,,5.798,1.9,2.1419,2.8517,3.58k,2.53k,44.19M,,34.32M,15.19%,33.04%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",0.00%,0.00%,-15.38%,-26.52%,,,,,-31.89M,-31.88M,-1.1000,,137.57M,3.11,468.56k,0.34,17.68,3.14,-36.42M,-25.39M,Value,07745,Healthcare,47,"InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.",Jena,49 3641 508 180,Germany,http://www.inflarx.de,86400,Winzerlaer Str. 2,Biotechnology
t-1,IF0.DE,77513697,44186300,5782479,,-8858421,,-8858421,2409436,0,-8174955,-8174955,-16960,-26000,,,,0,0,8174955,0,-683466,,-8858421,-8858421,350183,220289876,10351954,77863880,132727,88215834,3387410,98375,-168345620,33322,22532214,353522,25968681,10098107,22532214,954957,86284904,272268,55162033,1419490,1741251,-7839601.0,-1740319.0,-7849936.0,-90833.0,-90833.0,-786149.0,66106284.0,-18865408.0,-1199175.0,-9725465.0,49063.0,-4219222.0,1480398.0,-10334.0,-1.0,76186797,en-US,US,EQUITY,False,Delayed Quote,EUR,False,False,0,0.24000013,0.12631586,1.9 - 5.798,-3.6579998,-0.6309072,1.9,5.798,-1.1,-2.3722541,2.14 - 2.14,2.192,2.126,2.21,finmb_42434000,XETRA,InflaRx N.V.,EUR,3575,2531,3.142,2.1418571,-0.0018570423,-0.00086702436,2.8517466,-0.71174645,-0.24958265,94558688,0.6810949,15,Europe/Berlin,CEST,7200000,4,GER,REGULAR,de_market,"INFLARX N.V.  EO 0,12",2.14,1630569119,-0.051999807,2.14,2.14,2.14,1000,0.48,,,5.798,1.9,2.1419,2.8517,3.58k,2.53k,44.19M,,34.32M,15.19%,33.04%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",0.00%,0.00%,-15.38%,-26.52%,,,,,-31.89M,-31.88M,-1.1000,,137.57M,3.11,468.56k,0.34,17.68,3.14,-36.42M,-25.39M,Value,07745,Healthcare,47,"InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.",Jena,49 3641 508 180,Germany,http://www.inflarx.de,86400,Winzerlaer Str. 2,Biotechnology
t-2,IF0.DE,89315363,44186300,5246536,,-6858964,,-6858964,1166070,0,-6409148,-6409148,-3458,-26000,,,,0,0,6409148,0,-449816,,-6858964,-6858964,379811,220289876,11626288,89695174,36001,101321462,3387410,98374,-159487199,35488,25505087,385837,44834089,11467747,25505087,1091389,99191977,272448,50563814,1172907,9998452,8987809.0,-632010.0,8939061.0,-91353.0,8949750.0,-1183007.0,9770944.0,8435512.0,-873338.0,-8579961.0,179711.0,-729841.0,-85691.0,-48748.0,-1.0,87724230,en-US,US,EQUITY,False,Delayed Quote,EUR,False,False,0,0.24000013,0.12631586,1.9 - 5.798,-3.6579998,-0.6309072,1.9,5.798,-1.1,-2.3722541,2.14 - 2.14,2.192,2.126,2.21,finmb_42434000,XETRA,InflaRx N.V.,EUR,3575,2531,3.142,2.1418571,-0.0018570423,-0.00086702436,2.8517466,-0.71174645,-0.24958265,94558688,0.6810949,15,Europe/Berlin,CEST,7200000,4,GER,REGULAR,de_market,"INFLARX N.V.  EO 0,12",2.14,1630569119,-0.051999807,2.14,2.14,2.14,1000,0.48,,,5.798,1.9,2.1419,2.8517,3.58k,2.53k,44.19M,,34.32M,15.19%,33.04%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",0.00%,0.00%,-15.38%,-26.52%,,,,,-31.89M,-31.88M,-1.1000,,137.57M,3.11,468.56k,0.34,17.68,3.14,-36.42M,-25.39M,Value,07745,Healthcare,47,"InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.",Jena,49 3641 508 180,Germany,http://www.inflarx.de,86400,Winzerlaer Str. 2,Biotechnology
t-3,IF0.DE,90719007,44186300,7356326,,-10032832,,-10032832,2326895,0,-9584339,-9584339,-98882,-3111,,,,0,0,9584339,0,-448493,,-10032832,-10032832,404251,211483756,12747010,91123258,36000,103870268,3152427,1150837,-152628234,37644,29115309,419424,36398578,12505730,29115309,1210248,101563718,272627,62191912,1225552,10630462,22996046.0,139524.0,22988626.0,-95631.0,401315.0,1017147.0,496946.0,15314969.0,-373555.0,-7701416.0,171620.0,-729841.0,1003125.0,-7421.0,1.0,89057988,en-US,US,EQUITY,False,Delayed Quote,EUR,False,False,0,0.24000013,0.12631586,1.9 - 5.798,-3.6579998,-0.6309072,1.9,5.798,-1.1,-2.3722541,2.14 - 2.14,2.192,2.126,2.21,finmb_42434000,XETRA,InflaRx N.V.,EUR,3575,2531,3.142,2.1418571,-0.0018570423,-0.00086702436,2.8517466,-0.71174645,-0.24958265,94558688,0.6810949,15,Europe/Berlin,CEST,7200000,4,GER,REGULAR,de_market,"INFLARX N.V.  EO 0,12",2.14,1630569119,-0.051999807,2.14,2.14,2.14,1000,0.48,,,5.798,1.9,2.1419,2.8517,3.58k,2.53k,44.19M,,34.32M,15.19%,33.04%,,,,,,,,,,,0.00%,,,,,"Dec 31, 2020","Mar 31, 2021",0.00%,0.00%,-15.38%,-26.52%,,,,,-31.89M,-31.88M,-1.1000,,137.57M,3.11,468.56k,0.34,17.68,3.14,-36.42M,-25.39M,Value,07745,Healthcare,47,"InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.V. has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.",Jena,49 3641 508 180,Germany,http://www.inflarx.de,86400,Winzerlaer Str. 2,Biotechnology
